Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | WEE1 | P30291 | 3/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336929 | 0.87 | MAPK14 (0.79) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL16573714 | 0.87 | MAPK14 (1.00) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6336323 | 0.87 | MAPK14 (0.79) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6336928 | 0.87 | MAPK14 (0.79) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6337244 | 0.87 | MAPK14 (0.79) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6336324 | 0.87 | MAPK14 (0.79) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6337176 | 0.86 | MAPK14 (0.78) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6335282 | 0.84 | MAPK14 (0.75) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6335280 | 0.84 | MAPK14 (0.75) | MAPK14LCKFGFR1MAPK8ABL1 | |
| SCHEMBL6337480 | 0.82 | MAPK14 (0.71) | MAPK14LCKFGFR1MAPK8ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861423-B2 | Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds | SYNTEX (U.S.A.) LLC (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | SYNTEX (U.S.A) LLC | 2003-08-14 | — | — | US | disclosed |
| US-6506749-B2 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2003-01-14 | — | — | US | disclosed |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | MAPK1, MAP3K1, CDK1 | MAPK14 101/4885LCK 391/4885FGFR1 333/4885 |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | AR, PARP1, DPYD | MAPK14 4164/4885LCK 1388/4885FGFR1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.